EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CD74-Targeting Antibody–Drug Conjugate Enhances Immunosuppression of Glucocorticoid in Systemic Lupus Erythematosus

Qizhen Du, Shengtao Yao, Yuying Huang, Jia Zhang, Wangmo Sonam, Xiao Lu, Jichao Yang, Shipeng Cheng, Ran Wang, Jiefang Xu, Liyan Ma, Yu Liu und 7 weitere

International Journal of Molecular Sciences · 04.12.2025 · 26 (23) · 11761

DOI: 10.3390/ijms262311761 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 04.12.2025. Verfasst von Qizhen Du und 18 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Multicellular Systems, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Un…. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Immunoconjugates, Glucocorticoids, Histocompatibility Antigens Class II. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucocorticoid drugs (GCs), while effective in systemic lupus erythematosus (SLE), cause severe systemic side effects due to lack of tissue-specificity. To overcome this bottleneck, we developed a CD74-directed antibody–drug conjugate (Bud-ADC) to deliver budesonide, a potent GC drug, selectively to target CD74-expressing immune cells (e.g., B cells, dendritic cells), which play an important role in SLE pathogenesis. Bud-ADC combines a cross-species anti-CD74 antibody with budesonide via a cleavable linker, enabling immunosuppression on targeted cells. In vitro, Bud-ADC selectively inhibited CD74-high immune cell activation and cytokine production. In two SLE mouse models, Bud-ADC significantly alleviated disease hallmarks—reducing autoantibodies, splenomegaly, and kidney damage—while showing superior efficacy to free budesonide at equivalent doses. The therapeutic effects involved both direct targeting of CD74-high immune cells and indirect modulation of T cell responses despite low CD74 expression. This study establishes CD74-targeted ADC as a novel strategy to enhance GC efficacy in SLE, aiming at minimizing off-target toxicity while maintaining broad immunosuppressive activity. The translatable design supports further preclinical and clinical development for autoimmune diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, SystemicImmunoconjugatesGlucocorticoidsHistocompatibility Antigens Class IIAntigens, Differentiation, B-LymphocyteBudesonideImmunosuppressive AgentsAnimalsMiceHumansDisease Models, AnimalFemaleImmunosuppression Therapy

Stichwörter der Autor:innen

anti-CD74 antibodyantibody-drug conjugates (ADC)budesonideglucocorticoid (GC)systemic lupus erythematosus (SLE)

Substanzen

ImmunoconjugatesGlucocorticoidsHistocompatibility Antigens Class IIinvariant chainAntigens, Differentiation, B-LymphocyteBudesonideImmunosuppressive Agents

Autor:innen und Institutionen

  • Key Laboratory of Multicellular Systems, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, University of Chinese Academy of Sciences, Chinese Academy of Sciences,…
  • Shanghai Pharmaceuticals Holding Co., Ltd., Halei Road 898, Shanghai 201203, China.
  • School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.
  • Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230052, China.
  • Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, University of Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031, China.

ORCID-Profile: Xuelei Wang, Wei Lu, Zhiyang Ling

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Du, Q., Yao, S., Huang, Y., Zhang, J., Sonam, W., Lu, X., Yang, J., Cheng, S., Wang, R., Xu, J., Ma, L., Liu, Y., Wu, G., Zhang, J., Wang, X., Lu, W., Ling, Z., Yi, C., & Sun, B. (2025). CD74-Targeting Antibody–Drug Conjugate Enhances Immunosuppression of Glucocorticoid in Systemic Lupus Erythematosus. International Journal of Molecular Sciences, 26(23), 11761. https://doi.org/10.3390/ijms262311761

Vancouver

Du Q, Yao S, Huang Y, Zhang J, Sonam W, Lu X, et al. CD74-Targeting Antibody–Drug Conjugate Enhances Immunosuppression of Glucocorticoid in Systemic Lupus Erythematosus. International Journal of Molecular Sciences. 2025;26(23):11761. doi:10.3390/ijms262311761

BibTeX
@article{Du2025,
  author = {Du, Qizhen and Yao, Shengtao and Huang, Yuying and Zhang, Jia and Sonam, Wangmo and Lu, Xiao and Yang, Jichao and Cheng, Shipeng and Wang, Ran and Xu, Jiefang and Ma, Liyan and Liu, Yu and Wu, Guanghao and Zhang, Jing and Wang, Xuelei and Lu, Wei and Ling, Zhiyang and Yi, Chunyan and Sun, Bing},
  title = {CD74-Targeting Antibody–Drug Conjugate Enhances Immunosuppression of Glucocorticoid in Systemic Lupus Erythematosus},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {23},
  pages = {11761},
  doi = {10.3390/ijms262311761}
}
Kostenlos starten →